Short-acting GLP-1 agonists like exenatide (taken twice daily) may produce more immediate effects on post-meal glucose levels, whilst longer-acting weekly formulations such as semaglutide or dulaglutide provide more sustained action but may take longer to reach steady-state concentrations in the body

Key features include: 99% purity, confirmed by HPLC and mass spectrometry for analytical accuracy and research reproducibility Pentapeptide structurewith non-proteinogenic residues (Aib and D-amino acids) conferring exceptional metabolic stability and resistance to non-specific proteolytic degradation High receptor selectivitydemonstrating minimal activity on non-target pituitary hormones including ACTH, cortisol, prolactin, FSH, LH, and TSHdistinguishing it from less selective growth hormone secretagogues Potent GHS-R1a agonist activitywith ED = 2.3 nmol/kg in conscious animal models, comparable to GHRP-6 efficacy but with enhanced selectivity Lyophilized powder formatproviding extended shelf-life stability of up to 24 months when stored appropriately, with minimal degradation under recommended cold-storage conditions Widely utilized as a pharmacological tool compoundfor structure-activity relationship (SAR) investigations and receptor-ligand selectivity studies For laboratory research use only These properties support its use as ipamorelin for research across receptor pharmacology, endocrine signaling, and growth hormone axis investigations

Foundayo has not been approved for type 2 diabetes
A high intake of antioxidants, such as flavonoids and The antioxidant activity of GSE has shown potential to inhibit human breast, lung, gastric, oral squamous cell, liver, prostate, and pancreatic cell lines in lab settings
and are used with permission
These compounds belong to a class called growth hormone-releasing peptides (GHRPs), which directly activate receptors in the brain that trigger the pituitary gland to release natural growth hormone (GH)